Dashboard
Analysis
Charting
Screener
Resources
Settings
NYSE-DNA
Dec '19
Dec '20
Dec '21
Dec '22
Dec '23
Dec '24
Cell Engineering Revenue
29.4
39.1
Biosecurity Product Revenue
—
Biosecurity Service Revenue
9.5
10.5
Total Biosecurity Revenue
Total Revenue
38.8
49.6
Cell Engineering Operating Income
-36.7
-9.9
Biosecurity Operating Income
-4.9
-4.8
Corporate Operating Income
Total EBIT
-90
-65.5
New Programs
Current Active Programs
Cumulative Programs